Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.